Relationships between the pharmacological treatment method and negative symptoms, depression, social functioning and quality of life in schizophrenia patients during 11–15 years after a first psychiatric hospitalisation

Krystyna Jaracz; Krystyna Górna; Justyna Kiejda; Katarzyna Gołębiewska; Jan Jaracz

doi:10.5114/fpn.2022.117698

eISSN: 2449-9315
ISSN: 1234-8279

Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

Open access

1/2022
vol. 38

Send email

Copy url:

Original article

Relationships between the pharmacological treatment method and negative symptoms, depression, social functioning and quality of life in schizophrenia patients during 11–15 years after a first psychiatric hospitalisation

Krystyna Jaracz

¹

,

Krystyna Górna

²

,

Justyna Kiejda

²

,

Katarzyna Gołębiewska

²

,

Jan Jaracz

³

Department of Neurological Nursing, Poznan University of Medical Sciences, Poznan, Poland;
Zakład Pielęgniarstwa Neurologicznego, Uniwersytet Medyczny w Poznaniu, Polska
Department of Psychiatric Nursing, Poznan University of Medical Sciences, Poznan, Poland;
Zakład Pielęgniarstwa Psychiatrycznego, Uniwersytet Medyczny w Poznaniu
Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland;
Klinika Psychiatrii Dorosłych, Uniwersytet Medyczny w Poznaniu, Polska

Farmakoterapia w Psychiatrii i Neurologii 2022, 38 (1), 23–33

DOI: https://doi.org/10.5114/fpn.2022.117698

Online publish date: 2022/08/02

Article file

- 02R_IPiN_FARM_2022-1C.pdf [0.32 MB]

Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Jaracz K, Górna K, Kiejda J, Gołębiewska K, Jaracz J. Relationships between the pharmacological treatment method and negative symptoms, depression, social functioning and quality of life in schizophrenia patients during 11–15 years after a first psychiatric hospitalisation. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii. 2022;38(1):23-33. doi:10.5114/fpn.2022.117698.

APA

Jaracz, K., Górna, K., Kiejda, J., Gołębiewska, K.,  & Jaracz, J. (2022). Relationships between the pharmacological treatment method and negative symptoms, depression, social functioning and quality of life in schizophrenia patients during 11–15 years after a first psychiatric hospitalisation. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii, 38(1), 23-33. https://doi.org/10.5114/fpn.2022.117698

Chicago

Jaracz, Krystyna, Krystyna Górna, Justyna Kiejda, Katarzyna Gołębiewska,  and Jan Jaracz. 2022. "Relationships between the pharmacological treatment method and negative symptoms, depression, social functioning and quality of life in schizophrenia patients during 11–15 years after a first psychiatric hospitalisation". Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii 38 (1): 23-33. doi:10.5114/fpn.2022.117698.

Harvard

Jaracz, K., Górna, K., Kiejda, J., Gołębiewska, K.,  and Jaracz, J. (2022). Relationships between the pharmacological treatment method and negative symptoms, depression, social functioning and quality of life in schizophrenia patients during 11–15 years after a first psychiatric hospitalisation. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii, 38(1), pp.23-33. https://doi.org/10.5114/fpn.2022.117698

MLA

Jaracz, Krystyna et al. "Relationships between the pharmacological treatment method and negative symptoms, depression, social functioning and quality of life in schizophrenia patients during 11–15 years after a first psychiatric hospitalisation." Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii, vol. 38, no. 1, 2022, pp. 23-33. doi:10.5114/fpn.2022.117698.

Vancouver

Jaracz K, Górna K, Kiejda J, Gołębiewska K, Jaracz J. Relationships between the pharmacological treatment method and negative symptoms, depression, social functioning and quality of life in schizophrenia patients during 11–15 years after a first psychiatric hospitalisation. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii. 2022;38(1):23-33. doi:10.5114/fpn.2022.117698.

PlumX metrics:

1. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry. Suppl. 1993; 22: 39-44.

2. Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S. The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry 1990;157: 853-859.

3. Bobes J, Arango C, Garcia-Garcia M, Rejas J. CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry 2010; 71(3): 280-286.

4. Bucci P, Mucci A, van Rossum IW, Aiello C, Arango C, Baandrup L i wsp. Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning. Eur Neuropsychopharmacol 2020; 34: 76-86.

5. Cerveri G, Gesi C, Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat 2019; 15: 1525-1535.

6. Correll CU, Schooler NR. Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat 2020; 16: 519-534.

7. Galderisi S, Kaiser S, Bitter I, Nordentoft M, Mucci A, Sabé M i wsp. EPA guidance on treatment of negative symptoms in schizophrenia. Eur Psychiatry 2021; 64(1): e21. (a)

8. Galderisi S, Mucci A, Dollfus S, Nordentoft M, Falkai P, Kaiser S i wsp. EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatry 2021; 1864(1): e23. (b)

9. García-Fernández L, Romero-Ferreiro V, Sánchez-Pastor L, Dompablo M, Martínez-Gras I, Espejo-Saavedra JM i wsp. Impact of negative symptoms on functioning and quality of life in first psychotic episodes of schizophrenia. J Clin Med 2022; 11(4): 983.

10. Górna K, Jaracz K, Jaracz J, Kiejda J, Grabowska-Fudala B, Rybakowski J. Funkcjonowanie społeczne i jakość życia u chorych na schizofrenię – zależność z remisją objawową i czasem trwania choroby. Psychiatr Pol. 2014; 48(2): 277-88.

11. Górna K, Jaracz K, Rybakowski F, Rybakowski J. Determinants of objective and subjective quality of life in first-time-admission schizophrenic patients in Poland: a longitudinal study. Qual Life Res. 2008; 17(2): 237-247.

12. an der Heiden W, Leber A, Häfner H. Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2016; 266(5): 387-396.

13. Jaracz J, Tetera-Rudnicka E, Kujath D, Raczyńska A, Stoszek S, Czernaś W i wsp. The prevalence of antipsychotic polypharmacy in schizophrenic patients discharged from psychiatric units in Poland. Pharmacol Rep 2014; 66(4): 613-617.

14. Jaracz K, Górna K, Kiejda J, Grabowska-Fudala B, Jaracz J, Suwalska A, Rybakowski JK. Psychosocial functioning in relation to symptomatic remission: A longitudinal study of first episode schizophrenia. Eur Psychiatry 2015; 30(8): 907-913.

Relationships between the pharmacological treatment method and negative symptoms, depression, social functioning and quality of life in schizophrenia patients during 11–15 years after a first psychiatric hospitalisation

Krystyna Jaracz 1 , Krystyna Górna 2 , Justyna Kiejda 2 , Katarzyna Gołębiewska 2 , Jan Jaracz 3

Krystyna Jaracz

¹

,

Krystyna Górna

²

,

Justyna Kiejda

²

,

Katarzyna Gołębiewska

²

,

Jan Jaracz

³